Your browser doesn't support javascript.
loading
Perceptions of healthcare professionals on the use of Mepitel Film for the prevention of acute radiation dermatitis in breast cancer.
Rajeswaran, Thenugaa; Kennedy, Samantha K F; Gojsevic, Milena; Herst, Patries; Safavi, Amir H; Corbin, Kimberly; Hill, Rosemary; Karam, Irene; Tran, William; Gallant, François; Carothers, Katherine; Lam, Jacqueline; Trombetta, Mark; Arscott, William T; Shariati, Saba; Akkila, Shereen; Behroozian, Tara; Zhang, Elwyn; Chow, Edward.
Affiliation
  • Rajeswaran T; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
  • Kennedy SKF; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
  • Gojsevic M; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
  • Herst P; Department of Radiation Therapy, University of Otago, Wellington, New Zealand.
  • Safavi AH; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
  • Corbin K; Department of Radiation Oncology, Mayo Clinic, Rochester, USA.
  • Hill R; Lions Gate Hospital, Vancouver, British Columbia, Canada.
  • Karam I; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
  • Tran W; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
  • Gallant F; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
  • Carothers K; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
  • Lam J; Health Sciences North, Sudbury, Ontario, Canada.
  • Trombetta M; Sault Area Hospital, Sault Ste. Marie, Ontario, Canada.
  • Arscott WT; Division of Radiation Oncology, Allegheny General Hospital, Drexel University College of Medicine, Pittsburgh, USA.
  • Shariati S; Division of Radiation Oncology, West Cancer Center, Compass Oncology, Tigard, USA.
  • Akkila S; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
  • Behroozian T; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
  • Zhang E; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
  • Chow E; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
Support Care Cancer ; 31(12): 725, 2023 Nov 28.
Article de En | MEDLINE | ID: mdl-38012460
ABSTRACT

INTRODUCTION:

Randomized clinical trials support Mepitel Film (MF) as a prophylactic treatment for radiation dermatitis (RD) in patients undergoing breast radiotherapy. Although several studies have canvassed the opinion of patients on using MF, no such studies have been done to investigate the perception of healthcare professionals (HCPs). The objective of this study was therefore to investigate the perceptions of HCPs on MF as a treatment option for RD.

METHODS:

Anonymized responses to a web-based survey sent to HCPs at a single institution managing patients using MF during breast radiotherapy were analyzed.

RESULTS:

Of the 28 HCPs contacted, 22 completed the survey, including 6 radiation oncologists (ROs), 11 radiation therapists (RTTs), and 5 nurses. Most HCPs reported MF was better at preventing severe RD than the standard of care and improved radiation-induced skin reactions (n = 20/22, 91%, and n = 19/22, 86%, respectively). MF was recommended for mastectomy patients without reconstruction (n = 15/21, 71%). The majority of HCPs believed that patients' families could be trained to apply and remove MF (n = 19/22, 86%). Many HCPs perceived that implementation of MF would be difficult in terms of maintaining patient flow and wide-scale implementation within their institution (n = 11/22, 50%, and n = 10/22, 46%, respectively). Most HCPs perceived that fewer than 50% of their patients could afford MF if priced at $100 CAD (n = 15/20, 75%).

CONCLUSION:

These findings provide insights into the possibility of MF to be incorporated into standard practice of care for RD. Although most HCPs were satisfied with MF as a prophylactic treatment for RD, there are concerns about its resource-intensive operationalization and financial accessibility to patients. Future research should focus on ways to improve HCP experience with MF and to improve its implementation into clinical settings as standard of care.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Radiodermite / Tumeurs du sein Limites: Female / Humans Langue: En Journal: Support Care Cancer Sujet du journal: NEOPLASIAS / SERVICOS DE SAUDE Année: 2023 Type de document: Article Pays d'affiliation: Canada

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Radiodermite / Tumeurs du sein Limites: Female / Humans Langue: En Journal: Support Care Cancer Sujet du journal: NEOPLASIAS / SERVICOS DE SAUDE Année: 2023 Type de document: Article Pays d'affiliation: Canada
...